Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.491
Revised: August 6, 2014
Accepted: August 30, 2014
Published online: September 26, 2014
Processing time: 70 Days and 12.9 Hours
Mesenchymal stem cells (MSCs), multipotential cells that reside within the bone marrow, can be induced to differentiate into various cells, such as osteoblasts, adipocytes, chondrocytes, vascular endothelial progenitor cells, and other cell types. MSCs are being widely studied as potential cell therapy agents due to their angiogenic properties, which have been well established by in vitro and in vivo researches. Within this context, MSCs therapy appears to hold substantial promise, particularly in the treatment of conditions involving skin grafts, pedicle flaps, as well as free flaps described in literatures. The purpose of this review is to report the new advances and mechanisms underlying MSCs therapy against skin flaps necrosis.
Core tip: Mesenchymal stem cells (MSCs) therapy appears to hold substantial promise in the treatment against skin flaps necrosis. This review involved four out of the top 10 innovations of the 20th century and four out of the 10 most important, current innovations. We hope that these contents could help you to pick up the new advances in the MSCs therapy against skin flaps necrosis.